Stock BIOEE BB BIOTECH AG
Add to a list
To use this feature you must be a member
Log inSign up

BB Biotech AG Share Price Swiss Exchange

Equities

BIOEE

CH0027659793

Biotechnology & Medical Research

Market Closed - Swiss Exchange
Other stock markets
 12:01:39 13/04/2022 pm IST 		5-day change 1st Jan Change
64.4 CHF +31.97% Intraday chart for BB Biotech AG -.--% -.--%
26/04 Switzerland's BB Biotech Swings to Q1 Profit; Operating Income Jumps MT
16/02 BB Biotech's Loss Narrows in FY23; Operating Income Down MT

Financials

Sales 2024 * 190M 208M 17.35B Sales 2025 * 101M 110M 9.19B Capitalization 2.22B 2.43B 203B
Net income 2024 * 152M 166M 13.88B Net income 2025 * 72M 78.72M 6.57B EV / Sales 2024 * 13.2 x
Net Debt 2024 * 291M 318M 26.57B Net Debt 2025 * 324M 355M 29.62B EV / Sales 2025 * 25.3 x
P/E ratio 2024 *
14.6 x
P/E ratio 2025 *
13.6 x
Employees 10
Yield 2024 *
5.81%
Yield 2025 *
5.93%
Free-Float 97.24%
More Fundamentals * Assessed data

Chart BB Biotech AG

Dynamic Chart

Latest news about BB Biotech AG

Switzerland's BB Biotech Swings to Q1 Profit; Operating Income Jumps MT
BB Biotech's Loss Narrows in FY23; Operating Income Down MT
BB Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BB Biotech Trims FY23 Dividend as Net Loss Narrows MT
BB Biotech Names Successor to Outgoing Chair MT
BB Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Switzerland's BB Biotech Swings to Q3 Loss; Operating Income Shrinks MT
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022. CI
BB Biotech Shares to be Suspended from Euronext Star Milan Pending Delisting MT
BB Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Switzerland's BB Biotech to Scrap Listing on Italian Bourse MT
BB Biotech Logs Decline in H1 Loss, Operating Income MT
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022. CI
BB Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Europeans contrasted; gold below USD2,000 threshold AN
More news

Analyst Recommendations on BB Biotech AG

BB BIOTECH : Baader Bank remains its Buy rating ZD
GLOBAL MARKETS LIVE: Honor, Google, Samsung… Our Logo
BB BIOTECH : Independant Research reaffirms its Neutral rating ZD
More recommendations

Press releases BB Biotech AG

BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates EQ
BB Biotech AG publishes its interim report EQ
DD: BB BIOTECH AG: Dr. Thomas von Planta, buy EQ
DD: BB BIOTECH AG: Dr. Thomas von Planta, buy EQ
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share EQ
More press releases

News in other languages on BB Biotech AG

Morning Briefing - Markt Schweiz
Principales informations avant-Bourse
BB Biotech se relève de sa lourde perte en 2023
BB Biotech legt soliden Start ins neue Jahr hin
BB Biotech AG veröffentlicht Zwischenbericht
More news

Highs and lows

1 week
64.40
Extreme 64.4
64.40
1 month
64.40
Extreme 64.4
64.40
Current year
64.40
Extreme 64.4
64.40
1 year
64.40
Extreme 64.4
64.40
3 years
48.80
Extreme 48.8
64.40
5 years
48.80
Extreme 48.8
248.50
10 years
45.20
Extreme 45.2
343.50
More quotes

Managers and Directors - BB Biotech AG

Managers TitleAgeSince
Daniel Koller CIO
 Chief Investment Officer 54 01/04/01
Tanja Chicherio
- -
Silvia Siegfried-Schanz
- -
Members of the board TitleAgeSince
Clive Meanwell BRD
 Director/Board Member 67 01/04/01
Mads Krogsgaard Thomsen BRD
 Director/Board Member 63 01/20/01
Thomas von Planta CHM
 Chairman 63 21/19/21
More insiders

Quotes

Date Price Change
26/24/26 64.4 -.--%
25/24/25 64.4 -.--%
24/24/24 64.4 -.--%
23/24/23 64.4 -.--%
22/24/22 64.4 -.--%

Delayed Quote Swiss Exchange, April 13, 2022 at 12:01 pm IST

More quotes

Company Profile

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Sector
Biotechnology & Medical Research
Calendar
26/07/2024 - Q2 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for BB Biotech AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
40.45 CHF
Average target price
47.7 CHF
Spread / Average Target
+17.92%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. BION Stock
  4. BIOEE Stock